Todd Campbell

Todd Campbell

TMFEBCapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent articles

warren-buffett-buys-apple-stock_large_large

Warren Buffett Just Bought These Stocks

Berkshire Hathaway's 13-F filing shows the Oracle of Omaha's bullish on healthcare.


GettyImages-1132186568

Amazon Opens an Online Pharmacy

The e-commerce giant's new pharmacy will deliver prescription drugs throughout most of the U.S.


GettyImages-1127055456

Supreme Court May Side With Obamacare Again

Comments by conservative justices suggest the Affordable Care Act can continue without an individual mandate.


GettyImages-1205778418

Why Fulgent Genetics Stock Is Soaring 11.2% Today

Coronavirus testing demand caused revenue and profit to surge last quarter.


GettyImages-1179979986

Why Seagen Shares Are Tumbling 12.5% Today

A broad market sell-off is trumping third-quarter results that outpaced analyst expectations.

GettyImages-637107694

Abiomed's Heart Pump Can Improve Outcomes in Some Patients

New trial data supports the use of the company's Impella heart pumps in high-risk patients undergoing surgery to treat their coronary heart disease.


GettyImages-1179979986

Why Selecta Biosciences Tumbled 34% Today

Disappointing phase 2 data casts doubt on SEL-212's future.


GettyImages-1149364911

Here's Why Healthcare Stocks Are Falling This Week

Justice Ruth Bader Ginsburg's death jeopardizes Obamacare's future, and that puts healthcare companies' revenue at risk.


GettyImages-1141354730

FDA Accepts Application for Bristol-Myers Squibb and bluebird bio's Multiple Myeloma CAR-T Therapy

The Food and Drug Administration's acceptance means it will issue a go/no-go decision on ide-cel in March 2021.


GettyImages-996828576

Roche Spends $451 Million to Acquire Inflazome's NLRP3 Program

The deal will provide the pharma giant with a unique new platform for tackling autoimmune diseases.

GettyImages-637107694

AstraZeneca's Lynparza Delivers Progression-Free Survival of Over 4 Years in Advanced Ovarian Cancer

The latest results from a long-term study of the drug enhance the case for its use.


GettyImages-1211456953

Moderna Plans to Produce 20 Million Doses of Its COVID-19 Vaccine Candidate in 2020

The biotech is ramping up production ahead of the results from its late-stage clinical study of mRNA-1273.


GettyImages-1127055456

New York Files Charges Against Johnson & Johnson Over Opioid Marketing

The healthcare giant is being charged with insurance fraud.


GettyImages-1141354730

Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid

Bristol-Myers Squibb has come to terms on an agreement to delay entry of a generic version of its multiple myeloma drug, Revlimid.


GettyImages-1212321498

Moderna Opens Its First Commercial Office in Europe

Its new operations in Switzerland will boost its EU presence as it aims to bring a COVID-19 vaccine to market worldwide.

GettyImages-637107694

Germany Awards $743 Million to BioNTech and CureVac for Coronavirus Vaccine Development

BioNTech and CureVac will use the new funding to advance COVID-19 research and development in Germany.


GettyImages-1183724539

Merck Inks Multibillion-Dollar Deal With Seattle Genetics, Including Equity

Merck is acquiring $1 billion in Seattle Genetics shares as part of a wide-ranging collaboration agreement.


GettyImages-1178374751

Pfizer Says It Could Know If Its COVID-19 Vaccine Candidate Works in October

The drugmaker's CEO said there was a more than 60% chance that they would know by the end of next month if BNT162b2 is effective.


GettyImages-996828576

Neurocrine Biosciences Officially Begins Marketing Its New Parkinson's Disease Drug

The much-anticipated launch of Ongentys has arrived.


GettyImages-637107694

Why Agenus Is Soaring 23.6% Today

Investor optimism is increasing ahead of an oral presentation at ESMO 2020.